Study Of Perennial Allergic Rhinitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00358475
First received: July 27, 2006
Last updated: April 11, 2013
Last verified: May 2012

July 27, 2006
April 11, 2013
June 2005
October 2005   (final data collection date for primary outcome measure)
Adverse events and laboratory blood test
Same as current
Complete list of historical versions of study NCT00358475 on ClinicalTrials.gov Archive Site
Change of nasal symptom score
Same as current
Not Provided
Not Provided
 
Study Of Perennial Allergic Rhinitis
Study of Perennial Allergic Rhinitis -Long Term Treatment Study-

This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc. Typical symptoms are sneezing, nasal congestion and pruritus and rhinorrhea.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Rhinitis, Allergic, Seasonal
Drug: GW685698
Other Name: GW685698
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
65
October 2005
October 2005   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Informed consent.
  • Outpatient.
  • Diagnosis of perennial allergic rhinitis with symptoms.
  • Able to comply with study procedures.

Exclusion criteria:

  • Significant concomitant medical condition.
  • Use of corticosteroids/allergy medications.
  • Laboratory abnormality.
  • Positive pregnancy test.
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00358475
FFR100688
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP